Lung Cancer

In the United States, the incidence of lung cancer has increased in those aged >74 years and will likely continue to rise.

A conversation with Denise R. Aberle, MD, on the National Lung Screening Trial (NLST) at the 12th International Lung Cancer Congress.

ASCO endorses a Canadian agency's outlook on ovarian ablation, chemotherapy limits for stage IV lung cancer patients, and supportive care antiemetic therapies.

Dr. Corey Langer from the Abramson Cancer Center Discusses the PARAMOUNT Study

Dr. Rex Yung from Sidney Kimmel Comprehensive Cancer Center Discusses Forming a Multidisciplinary Team

Dr. Gordon Mills from MD Anderson Cancer Center Gives Examples of Unexpected Therapy Responses

Dr. Giorgio Scagliotti from the University of Turin Gives 3 Important Lung Cancer Takeaway Points

Dr. Rex Yung from Sidney Kimmel Comprehensive Cancer Center on a Paradigm Shift in Lung Cancer Treatment

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Meeting.

Dr. Giorgio Scagliotti from University of Turin Discusses Elderly Lung Cancer Therapy

Dr. Heather Wakelee from the Stanford Clinical Cancer Center on the Future of Lung Cancer Adjuvant Therapy

Dr. Rex Yung from Sidney Kimmel Comprehensive Cancer Center Discusses the Evolving Role of the Pulmonologist

Dr. Heather Wakelee from Stanford Clinical Cancer Center on Using Lymph Nodes for Lung Cancer Staging

Dr. Giorgio V. Scagliotti from the University of Turin on Mechanisms of Resistance to EGFR TKIs

Dr. Corey J. Langer from Abramson Cancer Center Discusses the JMEN Maintenance Pemetrexed Trial

Dr. Kemp Kernstine from University of Texas, Southwestern Medical Center Discusses Variation in Thoracic Surgery Outcomes

Dr. Corey J. Langer from Abramson Cancer Center on Assessing Patient Populations in Clinical Trials

Roy S. Herbst, MD, PhD, is a physician and translational researcher, whose work in developing novel, personalized therapies for lung cancer has helped drive significant changes in the way the disease is treated.

The epidermal growth factor receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK) and one of the most comprehensively studied molecular targets in clinical oncology.

Welcome to UCD ChestHealth, the official blog of UC Davis Thoracic Surgery.

Dr. Heather Wakelee from Stanford Clinical Cancer Center Discusses Adjuvant Therapy Predictive Markers

The desire to reduce the risk and severity of treatment-related toxicity by rapidly discontinuing ineffective therapy, and the increasing use of highly sensitive imaging technology.

The investigational oral agent talactoferrin alfa reduces the risk of death in patients being treated in the intensive care unit for severe sepsis.

Dr. Giorgio Scagliotti from the University of Turin in Italy on EGFR Targeted Therapy Survival Benefits

Dr. Ken Y. Yoneda from UC Davis Cancer Center Discusses Pulmonary Nodules